Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCG-2025 Protocol for Newly Diagnosed I/HR-B-ALL
NCT06764238Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised trial of blinatumomab and venetoclax in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Event-Free Survival at 6.5 years. Started Jan 2025; status: recruiting.
02
Drugs
blinatumomabvenetoclax
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06764238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764238.